ASCO 2018 | Melanoma trial updates from ASCO 2018: CheckMate 238, KEYNOTE-001/006 & COLUMBUS

The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, hosted an array of exciting clinical trials updates in melanoma, as discussed here by Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy. Dr Ascierto covers: the CheckMate 238 study (NCT02388906); the 5-year KEYNOTE-001 (NCT01295827) update on survial and outcomes; the 4-year KEYNOTE-006 (NCT01866319) update; and the novel combination of encorafenib plus binimetinib (COLUMBUS; NCT01909453).